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Background: Certain mutations in the Deadend1 (Dnd1) gene are the most potent modifiers of testicular germ cell
tumor (TGCT) susceptibility in mice and rats. In the 129 family of mice, the Dnd1Ter mutation significantly increases
occurrence of TGCT-affected males. To test the hypothesis that he Dnd1Ter allele is a loss-of-function mutation; we
characterized the consequences of a genetically-engineered loss-of-function mutation in mice, and compared these
results with those for Dnd1Ter.
Results: We found that intercrossing Dnd1+/KO heterozygotes to generate a complete loss-of-function led to
absence of Dnd1KO/KO homozygotes and significantly reduced numbers of Dnd1+/KO heterozygotes. Further crosses
showed that Dnd1Ter partially rescues loss of Dnd1KO mice. We also found that loss of a single copy of Dnd1 in
Dnd1KO/+ heterozygotes did not affect baseline occurrence of TGCT-affected males and that Dnd1Ter increased TGCT
risk regardless whether the alternative allele was loss-of-function (Dnd1KO) or wild-type (Dnd1+). Finally, we found
that the action of Dnd1Ter was not limited to testicular cancer, but also significantly increased polyp number and
burden in the Apc+/Min model of intestinal polyposis.
Conclusion: These results show that Dnd1 is essential for normal allelic inheritance and that Dnd1Ter has a novel
combination of functions that significantly increase risk for both testicular and intestinal cancer.
Keywords: Testicular cancer, Allelic segregation, Intestinal neoplasia, DND1Background
Testicular germ cell tumors (TGCTs) are the most com-
mon cancer affecting young men. They are disproportion-
ately represented in men aged 20–40, comprising ~60% of
all cancers in this age group [1], while accounting for only
1.0-1.5 % of all cancers [2]. The incidence of TGCTs has
increased in the last 30 years [3], rising approximately 3%
per year from 1972 to 2002 [4] compared to an overall an-
nual decrease of 0.6% from 1994–2009 for all cancers
in men [5].
Testicular cancer is widely considered to be one of the
most heritable forms of cancer [6,7]. Genetic factors
contribute significantly to TGCT susceptibility as exem-
plified by a 4- to 15-fold increased risk in the sons and* Correspondence: jnadeau@pnri.org
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reproduction in any medium, provided the orbrothers of affected men, respectively [8,9]. With con-
ventional inheritance however, risk should be similar in
sons and brothers. The ~4-fold difference in occurrence
of affected sons and brothers implies that other modes
of inheritance are involved. Despite strong heritability,
known genetic mutations and single nucleotide polymor-
phisms (SNPs) make only modest contributions to sus-
ceptibility, illustrating the genetically complex nature of
this disease. The gr/gr deletion, which is a common
cause of infertility in men, is associated with increased
TGCT risk [10]. But its contribution is modest, occur-
ring in only 3% of TGCT cases with a family history and
1% of unaffected individuals [11]. gr/gr results from a 1.6
Mb deletion at the AZFc locus at Yq11 of the human Y
chromosome, a region that contains multiple copies of
several genes that are involved in male germ cell devel-
opment including DAZ (deleted in azospermia), BPY2
(basic charge, Y-linked 2) and CDY1 (chromodomain
protein, Y-linked 1). Effects of the gr/gr deletion onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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unknown.
Several single nucleotide polymorphisms (SNPs) are
associated with increased TGCT risk in humans. In par-
ticular, six studies implicate SNPs that are associated
with at least 14 genes: ATF7IP , BAK1, DMRT1, KITLG,
SPRY4, TERT, HPGDS, MAD1L1, RFWD3, TEX14,
RAD51C, PPM1E, DAZL and PRDM14 [12-19]. Molecu-
lar mechanisms remain unclear, in part because many
SNPs are located outside the coding region of the associ-
ated gene, and in part because the haplotype structure
and sequence of these loci have not yet been fully
reported. Interestingly, the TERT SNP is also associated
with adenocarcinoma [20].
Certain mutations in the Dead End 1 (Dnd1) gene are
potent modifiers of TGCT susceptibility in both mice
and rats. In the mouse, the spontaneous Dnd1Ter muta-
tion significantly increases TGCT susceptibility in the
129 family of inbred mouse strains. In particular,
Dnd1Ter increases occurrence of TGCT-affected males
from a baseline of ~5% in the 129S1/SvImJ strain to 17%
in Dnd1+/Ter heterozygotes and 94% in Dnd1Ter/Ter ho-
mozygotes [21,22]. The Ter mutation is a single base
substitution in exon 3, 3′ to its single RNA recognition
motif (RRM), that transforms an arginine residue to a
premature stop codon (Figure 1, see also [22]). The Ter
mutation has been proposed to produce an mRNA thatFigure 1 Structure of the Dnd1, Dnd1Ter and Dnd1KO genes and their
displayed above the solid line, and the corresponding protein product is d
Dnd1 which differ in the amino-terminus of the protein. Dnd1 has an RNA
HRAAAMA motif that is presumably part of the putative ATPase domain is
identified in human TGCTs include a (1) Glu86Ala [25] and (2) an Asp219Gl
at amino acid 178 (★3), which is located 37 nucleotides from the 3′ most e
codon at amino acid 289 (★4) within exon 4. The RRM is intact in both mo
recognize and bind to target RNAs; the putative ATPase domain is lost in t
retains the 3′ most portion of exon 3 and exon 4, but does not have a tranis lost by nonsense-mediated degradation owing to the
presence of the premature stop codon. This conclusion
was based on northern blots of mRNA isolated from
TGCTs in Dnd1Ter/Ter males [22]. But the tissue type
(TGCTs) used in this study may not have been appropri-
ate to assess the fate of Dnd1 transcripts.
In the rat, a spontaneous mutation has been identified
where a G to A substitution in exon 4 produces a pre-
mature stop codon that is thought to result in a 62
amino acid truncation at the C-terminus of the DND1
protein (Figure 1, see also [23]). This mutation leads to
germ cell tumors in males and females as well as to spon-
taneous metastases.
In humans, sequencing of TGCT candidate genes in
several large studies failed to detect a significant number
of DND1 mutations [4,24]. Of the two SNPs that were
identified, one (Glu86Ala) is located within the con-
served RRM of DND1 (Glu86Ala). The functional conse-
quences of this mutation on Dnd1 expression and
function or on TGCT risk are not known.
Dnd1 has many unique functions. Dnd1 shares signifi-
cant sequence similarity with A1cf, a gene that encodes the
RNA binding subunit of the Apobec1 cytidine deaminase
that edits specific sites in specific mRNAs [22]. Interest-
ingly, DND1 blocks access of specific miRNAs to their 3′
target in mRNAs such as p27, LATS2 and TDRD7 [26].
DND1 also binds several pluripotency factor mRNAsinferred predicted protein products. Gene arrangements are
isplayed below the solid line. Dnd1 has two isoforms: α-Dnd1 and β-
recognition motif (RRM) in the C-terminal portion of exon 3. The
located between amino acids 181–186 in the mouse genome. SNPs
u [24]. In the mouse, the Ter mutation creates a premature stop-codon
xon-exon junction. The rat Ter mutation has the premature stop
use and rat Dnd1 mutants allowing these proteins to possibly
he mouse Dnd1Ter and truncated in rat Dnd1Ter. The Dnd1KO allele
scriptional start site.
Table 1 Dnd1+/KO intercross – genotype distribution at
weaning




Dnd1KO segregation in intercrosses and backcrosses. Results are presented
after pooling data for both genders (Tables 1, 2, 3, 4), because occurrence of
females and males did not differ significantly (not shown).
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cell cycle including LATS2, TP53, p21 and p27 [27,28],
apoptotic factors such as BCLX and BAX [27], and is a
positive regulator of geminin mRNA translation through
binding to its 3′ UTR [29]. The role of DND1 in these
functions and complexes is unknown. DND1 transports
mRNA transcripts from germ cell nuclei to germ cell
granules [30]. Finally, Dnd1 is required for primordial
germ cell (PGC) survival [31]; PGCs are the stem cell for
TGCTs [32]. Together these observations implicate Dnd1
in many aspects of RNA translation control.
The Dnd1 gene in mouse has four exons and encodes an
α-isoform, which is 352 amino acids, and a β-isoform,
which is 340 amino acids (Figure 1). These isoforms are de-
rived through alternative splicing and differ by 12 amino
acids at the amino-terminus of the protein. DND1-α is
expressed in early embryos, whereas DND1-β is expressed
in the germ cells of the adult testis [33]. Both isoforms con-
tain a single RNA recognition motif (RRM) and a highly
conserved HRAAAMA motif (unpubl). This 7 amino acid
motif is found in most orthologues of Dnd1 and A1cf
(JHN, unpubl.). In zebrafish, ATPase activity has been at-
tributed to a variant of this motif in Dnd1 [34].
Several considerations suggest that the assumption that
Dnd1Ter leads to loss-of-function is erroneous. In vivo loss
of function using morpholinos to reduce expression in
zebrafish showed that Dnd1 is required for PGC survival
[31], possibly through an ATPase activity [34]. Although
TGCTs have been reported in zebrafish [35-37], reduced
Dnd1 expression was not sufficient for tumorigenesis.
However, because genetic background strongly regulates
TGCT susceptibility in mice and rats [23,38-40], absence of
TGCTs in the zebrafish study could implicate either the na-
ture of the mutation or genetic background as critical ele-
ments determining tumorigenic outcome.
To test whether TGCT susceptibility depends on the na-
ture of Dnd1 mutations, we generated a line of 129/SvImJ-
DndKO mice. We found that deficiency of Dnd1 leads to
highly biased allelic inheritance and that Dnd1Ter partially
restores normal inheritance. We also found that Dnd1Ter
acts distinctly from Dnd1KO to increase TGCT risk in a
dosage-dependent manner in 129S1/SvImJ males, whereas
Dnd1KO did not significantly affect susceptibility. Finally, re-
cent work suggests that susceptibility to both TGCTs and
intestinal polyposis share genetic predisposition [41] and
that DND1 is normally expressed in the intestine [42-46].
We therefore tested whether Dnd1Ter affects intestinal
tumorigenesis and found that Dnd1Ter significantly in-
creases polyp number and burden in Apc+/Min mice.
Results
Loss of Dnd1 homozygotes and heterozygotes
Unexpected results were found for Dnd1+/KO intercrosses
that were intended to produce Dnd1+/KO heterozygotesand Dnd1KO/KO homozygotes as well as Dnd1+/+ wild-type
controls for TGCT surveys. The genotypic distribution
among adult mice differed significantly from 1:2:1 Men-
delian expectations (Table 1; χ2 = 108.4, p<0.0001; two-
tailed test, 2 degrees of freedom). In particular, no
Dnd1KO/KO homozygotes were observed among 282 off-
spring (Table 1). To assess the extent of the deviation from
expectations, we assumed that the number of Dnd1+/+
mice (N = 120) corresponded to expectations, and then
extrapolated from this wild-type number to the expected
numbers of Dnd1+/KO heterozygotes (N = 240) and
Dnd1KO/KO homozygotes (N = 120) mice. In addition to a
complete deficiency of Dnd1KO/KO homozygotes, only 68%
(= 162/240) of the expected number of Dnd1+/KO hetero-
zygotes was found, suggesting that parental Dnd1+/KO het-
erozygosity either biased segregation against the Dnd1KO
allele, or alternatively that partial or complete loss of
Dnd1 function led to lethality for Dnd1KO/KO homozygotes
and reduced viability for Dnd1+/KO heterozygotes.
To examine the developmental timing of genotypic
loss, we time-mated heterozygous Dnd1+/KO males and
females, and flushed embryonic day 3.5 (E3.5) embryos
from the oviduct. Embryos (N=25) were individually cul-
tured for one week before genotyping. The genotypic
distribution differed significantly from 1:2:1 Mendelian
expectations (Table 2; χ2 = 22.4, p<0.0001; two-tailed
test, 2 degrees of freedom). No Dnd1KO/KO homozygotes
were found among 25 cultured embryos, the number of
Dnd1+/KO heterozygotes was significantly reduced, and
no evidence was found for unfertilized oocytes. In
addition, the genotypic distributions for E3.5 embryos
(Table 2) and for adult mice (Table 1) did not differ sig-
nificantly (not shown). These results confirm observa-
tions found among adult mice and suggests that reduced
Dnd1 function either biased segregation, or led to early
embryonic lethality. Interestingly, unusual inheritance
patterns have also been reported for Apobec1KO –
Dnd1Ter interactions tests [47] and for Apobec1 comple-
mentation factor A1cf, the paralog of Dnd1 [48].
To test whether allelic segregation in Dnd1+/KO is inher-
ently biased, we examined the genotypic representation
in reciprocal backcrosses of Dnd1+/KO heterozygotes to
Dnd1+/+wild-type mice. Segregation did not differ signifi-
cantly from 1:1 Mendelian expectations for either
Table 2 Dnd1+/KO intercross – genotype distribution at
embryonic day 3.5 (E3.5)




Dnd1KO segregation in intercrosses and backcrosses. Results are presented
after pooling data for both genders (Tables 1, 2, 3, 4), because occurrence of
females and males did not differ significantly (not shown).
Table 4 Interaction between Dnd1Ter and Dnd1KO





Dnd1KO segregation in intercrosses and backcrosses. Results are presented
after pooling data for both genders (Tables 1, 2, 3, 4), because occurrence of
females and males did not differ significantly (not shown).
Male progeny (N=130) from crosses between Dnd1+/Ter and Dnd1+/KO mice.
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ingly, occurrence of Dnd1+/KO heterozygous progeny dif-
fered in intercrosses versus backcrosses of Dnd1+/KO
heterozygous parents, where a significant deficiency of
Dnd1+/KO heterozygotes was found among intercross but
not backcross progeny (Table 3). These results suggest
that segregation in each parent is normal and that gametes
in each parent are comparably functional in backcrosses
but not intercrosses.
Litter size can be used to determine whether unusual
inheritance patterns result from embryonic lethality. Lit-
ter size should be reduced substantially if deficiency of
some genotypes results from lethality. By contrast, if
production of gametes or fertilization is biased towards
particular alleles, litter sizes should not differ among the
various crosses. However, despite significant deviation
from the expected genotypic distributions (Table 1), lit-
ter sizes did not vary significantly among crosses
(Table 3). These results argue against lethality as the
cause of the unusual genotypic distributions.
Based on the premise that the DND1Ter protein is
translated instead of being lost through nonsense medi-
ated degradation, a single copy of Dnd1Ter may be suffi-
cient to at least partially rescue Dnd1KO/KO loss. To test
this hypothesis, we intercrossed mice heterozygous for
the Dnd1KO and Dnd1Ter mutations and examined
occurrence of the four genotypic classes among the
resulting offspring (Table 4). The distribution of Dnd1+/+,
Dnd1+/KO, Dnd1+/Ter, Dnd1KO/Ter offspring differed signifi-
cantly from 1:1:1:1 Mendelian expectations (χ2 = 9.1,
p<0.03; two-tailed test, 3 degrees of freedom). The genotype








Intercross 120 162 (240) 67.5 5.6±0.5 n=18
Backcross:maternal 110 107 (110) 97.2 5.8±0.4 n=30
Backcross:paternal 100 96 (100) 96 5.2±0.4 n=19
Dnd1KO segregation in intercrosses and backcrosses. Results are presented
after pooling data for both genders (Tables 1, 2, 3, 4), because occurrence of
females and males did not differ significantly (not shown).
*Mendelian expectations based on Dnd1+/+; litter size (mean ± SEM, n is the
number of litters).Dnd1KO/Ter heterozygote, which supports the hypothesis
that the DND1Ter protein is translated and retains sufficient
functionality to enable at least partial viability of animals in
the absence of wild-type DND1; if Dnd1Ter conferred loss
of function, then loss of both Dnd1KO/KO and Dnd1KO/Ter
should have been found.Dnd1 mRNA levels in Dnd1+/KO males
To determine whether the Dnd1KO allele leads to reduc-
tion of Dnd1 mRNA, Dnd1 transcript levels were
measured in heart and testis from Dnd1+/KO and wild-
type littermate control males that were 6–8 weeks old.
Dnd1+/KO mRNA levels were significantly reduced in
heart (0.41 ± 0.12; t = 3.1, p<0.05; two-tailed t-test, n=7)
and substantially reduced in testis (0.56 ± 0.19; n=7)
compared to their wild-type littermate controls (1.0 ±
0.06 and 1.0 ± 0.26; n=3 and 7, respectively) (Figure 2).
Dnd1 mRNA levels from Dnd1Ter/Ter hearts (1.33 ±
0.26) did not differ significantly from wild-type controls.
Testis samples were not tested because severe germ cell
deficiency in Dnd1Ter/Ter males would compromise inter-
pretation of any results [21,22,36]. These results confirmFigure 2 Dnd1 RNA levels in heart and testes. Dnd1 expression
cannot be measured reliably in Dnd1Ter/Ter testes because they
deficient in germ cells.
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Dnd1 mRNA levels.Germ cell numbers and fecundity in Dnd1-deficient males
We next sought to test whether Dnd1Ter and Dnd1KO al-
leles induce similar effects on PGC numbers in testes of
heterozygous and wild-type littermates from the Dnd1KO
line. Testes from Dnd1+/Ter males showed modest but sig-
nificant reductions in germ cell numbers and testis weight
[22,49]. We weighed testes from 6–10 week old Dnd1+/KO
males and their wild-type (+/+) littermates to determine if
they were phenotypically similar to those from Dnd1+/Ter.
Testes from wild-type males weighed an average of 4.43 ±
0.88g, which was similar to the average testes weight of
4.44 ± 0.69g in Dnd1+/KO heterozygotes (Additional file 1:
Figure S1A). These results suggest that germ cell numbers
were not significantly reduced in Dnd1+/KO males. Histo-
logical analysis confirmed these results for both Dnd1+/Ter
and Dnd1+/KO males (Additional file 1: Figure S1B & C).
Finally, both male and female heterozygotes for the
Dnd1KO allele were fertile as measured by the similar num-
ber of offspring produced in backcrosses to 129S1/SvImJ
(Table 3). Together these results suggest that the Dnd1KO
allele did not negatively impact germ cell numbers or
fertility.Table 6 Occurrence of TGCTs-affected males of various
Dnd1 genotypes
Genotype Affected Unaffected Affected males (%) (%)
+/+Dnd1 mutations and TGCT-affected males
To test whether partial Dnd1 deficiency affects occurrence
of affected males, Dnd1+/KO and their Dnd1+/+ wild-type
control littermates derived from Dnd1+/KO intercrosses
were surveyed for spontaneous TGCTs (Table 5). Signifi-
cant differences were not detected for occurrence of
TGCT-affected Dnd1+/KO heterozygous and Dnd1+/+
wild-type males. By contrast, 39% of Dnd1+/Ter males are
affected, which is significantly higher than the occurrence
of affected Dnd1+/KO and their Dnd1+/+ males (p<0.0001;
Fisher’s exact test, two-tailed, 1 degree of freedom). (This
rate for Dnd1+/Ter males in our colony is significantly
higher than published reports [50]. The rate has been con-
sistently higher for several years, without obvious explan-
ation. Because of the study design, this increased rate does
not affect results or interpretation in the present work.)
Thus, the Dnd1Ter but not the Dnd1KO mutation increases
TGCT risk.Table 5 Dnd1 genotype and occurrence of males affected
with at least one spontaneous TGCT
Genotype Affected Unaffected Affected males (%)
Dnd1+/+ 8 121 *6%
Dnd1+/KO 7 109 *6%
ǂDnd1+/Ter 35 90 39%
Dnd1+/KO males are offspring of both Dnd1+/+ × Dnd1+/KO and Dnd1+/KO ×
Dnd1+/+ reciprocal crosses. ǂ Results from Zechel et al. [51].To test whether the increased occurrence of affected
Dnd1Ter/Ter males was a result of increased Dnd1+/Ter or
the absence of Dnd1+/KO, we crossed Dnd1+/Ter and
Dnd1+/KO animals to generate compound heterozygous
Dnd1Ter/KO offspring that were surveyed for TGCTs
(Table 6). A single copy of Dnd1Ter increased occurrence
of TGCT-affected males from a baseline of 15% for
Dnd1+/+ wild-type males to 39% for Dnd1+/Ter males. A
second copy of Dnd1Ter (Dnd1Ter/Ter) further increased
occurrence of affected males to 98% [21,22]. We then
asked whether the higher occurrence of affected
Dnd1Ter/Ter males was due to the absence of wild-type
DND1, or a result of an increased dosage of Dnd1Ter.
Compound heterozygous males (Dnd1KO/Ter) have a rate
that does not recapitulate the rate found for Dnd1Ter/Ter
homozygotes (35% versus 97.8%, respectively) (Table 6).
Instead, the rate for compound heterozygotes was simi-
lar to the rate (34% and 39%) Dnd1+/Ter heterozygote.
These results suggest that DND1Ter protein has dose-
dependent effects on TGCT risk.
Dnd1Ter and intestinal polyposis
Although Dnd1Ter is a potent modifier of TGCT suscepti-
bility, we speculated that the tumorigenic properties of
Dnd1Ter may also be relevant in the intestine where Dnd1
is also expressed [52]. To test this hypothesis, we used the
Apc+/Min mouse model of intestinal polyposis. These mice
develop numerous intestinal polyps at an early age and are
a model of human Familial Adenomatous Polyposis (FAP)
[53]. We crossed Dnd1+/Ter and Apc+/Min mice to generate
compound Apc+/Min Dnd1+/Ter heterozygotes (test) as well
as a single-heterozygous Apc+/Min Dnd1+/+ control. After
100 days of age, a significant 1.5-fold increase in polyp
number was observed in Apc+/Min Dnd1+/Ter double-
heterozygous test males compared to Apc+/Min Dnd1+/+
control males (130 ± 1.3 and 96.2 ± 1.4, respectively; t =
4.4, p<0.001, two-tailed t-test; Figure 3A). Similarly, total
polyp mass was also significantly elevated from 192.2 ±
11.6 mm2 in Apc+/Min Dnd1+/+ mice to 352.6 ± 11.4 mm2
in Apc+/Min: Dnd1+/Ter males (t = 4.5, p<0.0001; two-tailed
t-test; Figure 3B), suggesting that a single copy of Dnd1TerǂDnd1 6 34 15%
ǂDnd1+/KO 1 28 3%
ǂDnd1+/Ter 14 27 34%
ǂDnd1KO/Ter 7 13 35%
*Dnd1+/Ter 35 55 ǂ39%
*Dnd1Ter/Ter 45 1 ǂ98%
Dnd1+/KO and Dnd1+/Ter animals were intercrossed to test for occurrence of
males with at least one TGCT. ǂ Offspring from Dnd1+/KO × Dnd1+/Ter crosses; *
offspring from Dnd1+/Ter × Dnd1+/Ter. ǂData are from Zechel et al. [51].
Figure 3 Polyp number (A) and mass (B) in C57BL/6-Apc+/Min
Dnd1+/Ter males. Males were surveyed for polyp number and mass
after 100 days on the 5010 diet.
Zechel et al. BMC Genetics 2013, 14:54 Page 6 of 10
http://www.biomedcentral.com/1471-2156/14/54exacerbates intestinal polyp initiation and development in
mice that are genetically susceptible to intestinal polyposis
and that the action of Dnd1Ter is not limited to
TGCTs.
Discussion
TGCTs are the third most heritable form of cancer, with
approximately 25% of the susceptibility being attributed
to underlying genetic factors [7]. The limited success in
identifying genetic variants that account for a significant
proportion of TGCT cases highlights the complex nature
of TGCT susceptibility [54-56]. Discovery of the gr/gr
deletion, together with validated SNPs in the ATF7IP,
BAK1, DMRT1, KITLG, SPRY4, TERT, HPGDS,
MAD1L1, RFWD3, TEX14, RAD51C, PPM1E, DAZL and
PRDM14 [12-19,57]. Even with these findings however,the majority of inherited TGCT susceptibility remains
unknown. In the mouse, several TGCT susceptibility
genes have been identified, including Kit, Kitlg, Pten,
Dmrt1, Eif2s2 and others (for a review, see [58]). Together
these human and mouse genes implicate pathways and
functions related to germ cell proliferation, PGC differen-
tiation and cell cycle control in TGCT development. But
much remains to be learned about the nature of mutations
in these genes that lead to tumorigenesis and about the
ways that these molecular changes disrupt these pathways.
The current study suggests that Dnd1Ter is not a loss-
of-function allele, but instead affects TGCT risk and em-
bryonic development in distinct ways from Dnd1KO, a
true loss-of-function mutation. The location of the point
mutation found within Dnd1 does not conform to the
“position of an exon-exon junction rule” for non-sense
mediated decay [59]. The premature Ter stop codon is
located 37 nucleotides upstream of the 3′-most exon-
exon junction, within the 50–55 nucleotide range that
fails to elicit nonsense-mediated decay (Figure 1). As a
result, a translated DND1Ter protein could be created
consisting of Dnd1 exons 1–2 and part of exon 3, with
an intact RRM but a disrupted HRAAAMA. The RRM
within DND1Ter may still recognize its target mRNAs,
but any functional or regulatory capabilities normally de-
rived from the deleted portion of DND1 would be ab-
sent. This supposition is supported by work with the rat
DND1Ter mutation, where the GFP-DND1Ter fusion pro-
tein is detectable in Huh7 cells [23]. The normal cellular
processes that DND1Ter might disrupt are numerous be-
cause RNA binding proteins have diverse functions, in-
cluding alternative splicing, RNA stability, miRNA
regulation, and translation control [60-63]. To date, anti-
bodies are not available for mouse DND1, thereby pre-
cluding many obvious studies.
Recent work revealed an essential role of a putative
ATPase domain in DND1 (RAAAE) in PGC survival
[34]. This previously unannotated domain shares hom-
ology with RAAA (amino acids 178–181) in mouse
DND1 where the arginine residue represents the amino
acid substituted with a stop codon in Dnd1Ter [22]. Thus
any ATPase activity in mouse DND1 possesses would be
lost in DND1Ter. This region is also part of a larger
motif in DND1, HRAAAMA, which is highly conserved
and found in many paralogous RNA binding proteins,
including Apobec complementation factor (A1CF),
suggesting that this motif is functionally important in
this gene family (unpubl.).
Although DND1Ter appears to be a novel variant that
increases TGCT risk, its tumorigenic effects are limited
to the 129 strain of mice, which is not surprising, since
this is the mouse strain that is susceptible to spontan-
eous TGCTs [38,63]. This finding highlights the import-
ance of genetic background on TGCT susceptibility,
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disparate TGCT rates among ethnic groups [4,64]. The
importance of genetic background is also evident in the
interaction of DND1Ter and mouse background. The 129
strain interacts positively with DND1Ter to increase
TGCT risk, whereas C56BL/6J and other strains only ex-
hibit phenotypes related to some but not all aspects of
mutations in genes such as Kit, Kitl, Pten, Eif2s2I and
other TGCT modifier genes, but not TGCTs [55,65,66].
However, the tumorigenic effects of Dnd1Ter are not lim-
ited to PGC transformation in the 129 strain mice.
C57BL/6J mice with the ApcMin mutation are highly sus-
ceptible to intestinal polyps [67]. However, when mice
are compound heterozygotes for both ApcMin and
Dnd1Ter, polyp numbers and polyp burden are signifi-
cantly increased (Figure 3). These results suggest that
DND1Ter affects pathways in both PGC transformation
and intestinal polyposis.
Embryonic lethality is the usual interpretation for
biased genotypic distributions in intercrosses, especially
with complete loss of homozygous mutants. However
this interpretation is difficult to reconcile with normal
litter sizes. In particular, loss of ~50% of intercross pro-
geny (Table 1) should lead to average litter sizes that are
~2 rather than ~4 pups per litter (Table 3). We are
aware of very few examples where substantial embryonic
lethality does not affect litter size [68]. Instead, we
propose that the unusual genotypic distributions result
from biased allelic inheritance where specific combina-
tions of oocyte and sperm are favored (or disfavored).
Normal segregation in reciprocal backcrosses with the
129S1/SvImJ suggests that gametes are produced in suf-
ficient numbers and are adequately functional (Table 3).
Instead results for intercrosses suggest that deficits in
both females and males are needed to bias allelic inherit-
ance. Together these results suggest that the bias arises
at fertilization. Interestingly, genetically and functionally
related genes also show biased segregation, including
Apobec1 and A1cf [47,48]
The contrasting effects of different classes of Dnd1
mutations may explain why sequencing studies failed to
yield mutations within DND1 in human TGCT cases
[24,25]. Complete loss of DND1 function is not suffi-
cient to promote TGCT formation, even on the TGCT-
susceptible 129S1/SvImJ inbred genetic background; re-
ducing the chances that DND1 mutations play a signifi-
cant role in human TGCTs. Results from zebrafish
support this interpretation. Loss of Dnd1 inhibits PGC
migration and results in PGC deficiency, but did not
produce TGCTs [31]. TGCTs have been previously
reported in zebrafish [35,49]. Dnd1Ter homozygotes also
show reduced migration and loss of PGCs, with typically
less than 20 PGCs arriving to the presumptive fetal go-
nads [21]. Instead, our results show that it is the loss ofthe carboxy-terminus of DND1 protein that increases
TGCT risk. The role of DND1Ter in TGCT formation is
further supported by recent results in a rat study where a
spontaneous mutation producing a premature stop codon
in exon 4, similar to DND1Ter, resulted in TGCTs [23]. To
date, human DND1 mutations have not yet been reported
that yield a similarly truncated DND1 protein.
Conclusions
Through intercrosses with mice carrying a complete loss
of function Dnd1KO allele our study showed that DND1
is necessary for embryonic viability and results in abnor-
mal allelic segregation. We have further shown that
Dnd1Ter, previously believed to be a loss-of-function al-
lele, is likely translated into a protein that retains some
normal DND1 function. Crosses with the Dnd1 knock-
out and Ter alleles revealed that the effects of the Ter al-
lele on TGCT incidence depend on Ter dosage.
Expression of the Ter allele in an APCMin model of in-
testinal polyposis also significantly increased polyp bur-
den. These results demonstrate that Dnd1Ter enhances




This strain (JR002448, previously known as 129/SvImJ)
was obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). All studies were conducted on this inbred
genetic background.
129S1/SvImJ-Dnd1+/KO
ES cells with a targeted deletion of Dnd1 were generated
from 129S6 mice by the Intrexon Corporation, (Blacksburg,
VA). Exons 1–2 and most of exon 3 of Dnd1 were removed
through homologous recombination (Additional file 2: Fig-
ure S2), and cells were negatively selected with thymidine
kinase (TK) and diphtheria toxin A (DTA), and positively
selected with neomycin. PCR was used to confirm homolo-
gous recombination in these cells. ES cells were then
injected into blastocysts (Case Transgenic and Targeting
Facility) and the resulting chimeras were backcrossed onto
the 129S1/SvImJ strain for more than 10 generations.
C57BL/6J (B6; JR000664) and C57BL/6J-Apc+/Min
(Apc+/Min; JR002020) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME).
From birth to 30 days of age, all mice were fed an
autoclaved standard laboratory diet (Purina 5010 LabDiet
(Richmond, IN) and were provided autoclaved water ad
libitum. All mice were maintained on a 12-h light/dark
cycle at the Wolstein Research Facility (CWRU).
Procedures were approved and conducted in compli-
ance with Institutional Animal Care and Use Committee
(IACUC) standards at (CWRU).
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Embryos from time-mated Dnd1+/KO X Dnd1+/KO preg-
nant females were flushed from the oviducts and uterine
horns on embryonic day 3.5 (E3.5) and cultured as pre-
viously described [69]. To obtain sufficient material for
reproducible genotyping, embryos were cultured for 1
week in individual wells of a 24-well tissue culture plate
Genotyping
DNA for PCR genotyping was extracted from tail tissue
(mice) or cell masses (E3.5 embryo cultures). The nu-
cleotide substitution in the Ter mutation results in the
creation of a Dde1 site that was used for genotyping
[22]. The Dnd1KO allele was amplified using primers
extending from exon 4 of Dnd1 into the neomycin gene
of the targeting construct. The Dnd1KO primers are:
CTGCGTGTTCGAATTCGCCAATGA (F), ACAAAG
AGAAACCCGGTCTCGGAA (R). Primers used for
genotyping Apc+/Min were previously described [67].
Tumor surveys
Male mice between the ages of 4–16 weeks were sur-
veyed for TGCTs. Tumor incidence was calculated as
the percentage of males with at least one TGCT. Histo-
logical analysis (H&E staining, see below) was used to
confirm any TGCTs that were ambiguous at autopsy.
Intestinal polyp survey
Mice were euthanized with cervical dislocation. The
small and large intestines were immediately removed,
flushed with cold PBS, and cut longitudinally for polyp
measurements. Polyps were counted and cross-sectional
diameter was measured in the small intestine and colon
with a Leica MZ10F Modular Stereomicroscope. Individ-
ual polyp size and number were used to calculate a
measure of total polyp mass for each mouse, and this
measure was used as a surrogate for polyp burden.
Histology
Testes were fixed with 10% formalin for at least 48h. Tis-
sues were then embedded in paraffin and sectioned (5 μm)
at the Case Comprehensive Cancer Center Tissue Procure-
ment and Histology Core facility (TPHC). Hematoxylin
and eosin staining was done in the TPHC facility.
Quantitative real-time PCR
RNA was extracted from cells and tissues using the
RNeasy micro- and mini-kits, respectively (Qiagen Inc.,
Valencia, CA) according to the manufacturer’s instruc-
tions and including an on-column DNAse treatment.
RNA was reverse-transcribed using the qScript Synthesis
Kit (Quanta BioSciences Inc., Gaithersburg, MD).
Changes in relative expression were quantified with the
Chromo4 real-time PCR system (MJ Research) andTaqMan primers to Dnd1(Invitrogen #Mm00849348)
and normalized to 18S (Invitrogen #4319413E) using
manufacturer protocols and reported as mean ± SEM.
Statistical analysis
Data are presented as mean ± SEM. Two-tailed t-tests
were used to evaluate results for quantitative PCR and
data for both polyp numbers and burden. Chi-square con-
tingency tests were used evaluate differences in occur-
rence of TGCT-affected males. Standard goodness-of-fit
tests were used to evaluate differences between observed
and Mendelian expectations for backcross and intercross
segregation results. Then, to estimate the extent of loss for
particular genotypes, the number of wild-type (+/+) mice
(or embryos) was taken as the expected number for this
genotypic class, and assuming Mendelian segregation (i.e.
1:2:1), the expected number of mutant heterozygotes and
homozygotes was calculated. The difference between these
observed and expected numbers was used to estimate the
extent of loss for each genotypic class.
Additional files
Additional file 1: Figure S1. Testis weight and histology in Dnd1+/+ and
Dnd1+/KO. (A) Testes were removed and weighed from mice aged 6 to 10
weeks. Testes weights from adult heterozygous Dnd1-deficient males (Het,
Dnd1+/KO) and their wild-type control littermates (WT, Dnd1+/+) were similar.
Testes from wild-type males (WT) weighed an average of 4.43 ± 0.88g,
compared to testes from heterozygous Dnd1+/KO males (4.44 ± 0.69g). Body
weights did not differ significantly between WT (Dnd1+/KO) and
heterozygous (Dnd1+/KO) animals (data not shown). Histology of these testes
show no morphological differences between Dnd1+/+ (B) and Dnd1+/KO
(C). These results suggest that testes in Dnd1+/KO males do not show
significant germ cell deficiency.
Additional file 2: Figure S2. Generation of Dnd1KO knockout mice. (A)
Genomic Dnd1 locus showing flanking Hars and Wdr55 genes. Exons are
shown as boxes and arrows show the direction of transcription. The left
and right homology arms of the targeting construct are indicated.
Following homologous recombination, exons 1, 2 and a portion of 3 of
Dnd1 are removed and a neomycin selection unit is introduced. The
triangle next to the neomycin unit indicates direction of transcription.
The Hars and Wdr55 genes remain intact.
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